Michael DiFiore

Rami Katkhuda

Jin Law

Matthew Caufield

Annabel Samimy

Mohit Bansal

Seamus Fernandez

Alice

Alice Nettleton

Colleen Garvey

Dennis Ding

Jayed Momin

Richard Law

Sadia Rahman

- Mineralys Therapeutics announced the pricing of an **upsized underwritten public offering** of **9,803,921 shares** of its common stock at **$25.50 per share** on September 2, 2025.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** 
- The offering is expected to generate approximately **$250.0 million** in gross proceeds  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]**  and **$234.7 million** in net proceeds for the company.  **[1933414_0001933414-25-000120_mlys-20250902.htm:1]** 
- Mineralys has granted underwriters a 30-day option to purchase up to an additional **1,470,588 shares**, which could increase net proceeds to approximately **$269.9 million** if fully exercised.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_mlys-20250902.htm:1]** 
- The net proceeds will be used to fund clinical development of **lorundrostat**, including research and development and manufacturing, pre-commercialization activities, working capital, and general corporate purposes.  **[1933414_0001933414-25-000120_exhibit991-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** 
- The offering is expected to close on or about **September 4, 2025**.  **[1933414_0001933414-25-000120_exhibit992-8xkseptember2025.htm:0]** **[1933414_0001933414-25-000120_mlys-20250902.htm:1]**

Mineralys Therapeutics Prices Upsized Public Offering

Mineralys Therapeutics (MLYS)